Login to Your Account

Clinic Roundup

Wednesday, November 16, 2011
• ProFibrix BV, of Leiden, the Netherlands, said its Phase II trial with Fibrocaps in liver resection surgery resulted in a 50 percent reduction in mean time to hemostasis – the primary endpoint – compared to active control. The study enrolled 56 patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription